BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
9.09
-0.04 (-0.44%)
Mar 13, 2026, 4:00 PM EDT - Market closed

BBOT Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-134.04-74.28-0.04-0
Depreciation & Amortization
0.610.21--
Stock-Based Compensation
5.874.43--
Other Adjustments
6.988.460.030
Changes in Other Operating Activities
6.696.160.02-
Operating Cash Flow
-113.89-55.03--
Capital Expenditures
-0.61-0.05--
Purchases of Investments
-83.93-154.43--
Proceeds from Sale of Investments
157.8631.54--
Other Investing Activities
-2.41--
Investing Cash Flow
73.33-120.53--
Issuance of Common Stock
373.51.11--
Net Common Stock Issued (Repurchased)
373.51.11--
Issuance of Preferred Stock
22.22205.18--
Net Preferred Stock Issued (Repurchased)
22.22205.18--
Other Financing Activities
-12.32---
Financing Cash Flow
383.4206.29--
Net Cash Flow
342.8430.73--
Free Cash Flow
-114.5-55.0800
Free Cash Flow Per Share
-3.68-4268.46--
Levered Free Cash Flow
-127.35-67.96-0.03-0
Unlevered Free Cash Flow
-139.13-74.54-0.03-0
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.